MMND-ITRO 2027

Program

We're putting together an exciting program featuring presentations, workshops, and more. The program is available below. Please note that the program is subject to change.

MMND-ITRO Program

8-13 February, 2027 | Mooloolaba QLD Australia

Program schedule

Day 1: Monday 8 February 2027

Registration and welcome

7.45-8.00 am: Assemble committee and speakers for session 1

8.00-8.10 am: Welcome
Anatoly Rozenfeld, Michael Lerch, and Tomas Kron

8.10-8.20 am: Official Opening of MMND
Alan Rowan, Deputy Vice-Chancellor (Research and Innovation), University of Wollongong, Australia

Session 1: Spatially fractionated radiation therapy (SFRT)

Session Chairs: Valentin Djonov, Olga Martin

  • 8.20-8.40 am: Dosimetry for SFRT: MRT and X-ray mini-beam
    Michael Lerch | CMRP, University of Wollongong, Australia
  • 8.40-9.00 am: SFRT: Current status and clinical implementation
    Valentin Djonov | University of Bern, Switzerland
  • 9.00-9.20 am: Clinical Minibeam experience at Mayo Clinic
    Sean Park | Mayo Clinic Rochester, USA
  • 9.20-9.40 am: Bringing MRT to patients: A road paved by paper, plastic and good intentions
    Thomas Breslin | Lund University, Sweden
  • 9.40-9.55 am: Sub-millimetre SFRT: A new frontier in radiation-induced anti-tumour immunity
    Verdiana Trappetti | University of Bern, Switzerland
  • 9.55-10.10 am: Weeks, Not Hours: Synchrotron microbeam radiotherapy induces a persistent blood–brain barrier permeability window in normal mouse brain
    Christian Fernandez | University of Bern, Switzerland
  • 10.10-10.30 am: TBC
    Elisabeth Schültke | Rostock University Medical Center, Germany

10.30-11.00 am: Morning tea and industry exhibition

Session 2: Spatially fractionated radiation therapy (SFRT) continued

Session Chairs: Tomas Kron, Stéphanie Corde

  • 11.00-11.20 am: Immune responses underlying the abscopal effect triggered by microbeam radiotherapy in a preclinical non-immunogenic tumour model
    Olga Martin | CMRP, University of Wollongong, Australia
  • 11.20-11.35 am: Microbeams un-leashed: promising outcomes for canine sarcoma treated with microbeam radiation therapy
    Elette Engels | Peter MacCallum Cancer Centre, Australia
  • 11.35-11.55 am: The first clinical microbeam source in Munich
    Stefan Bartzsch | Technical University of Munich, Germany
  • 11.55 am-12.15 pm: X-ray source prototype and grid manufacturing for sub-mm SFRT
    Martin Braeuer | Siemens Healthineers AG, Germany

12.15-1.30 pm: Lunch and industry exhibition

Session 3: Particle Therapy - Physics and Planning

Session Chairs: Linh Tran, Carl Rossi

  • 1.30-1.50 pm: Current status and future perspectives of charged-particle therapy
    Taku Inaniwa | National Institute for Quantum Science and Technology, Chiba, Japan
  • 1.30-2.10 pm: Radiobiology modelling – How do we crack it?
    Erik Traneus | RaySearch, Sweden
  • 2.10-2.30 pm: Dr Calc is back: updated results from dose rate calculations in PBS
    Nicolas Depauw | Massachusetts General Hospital, USA
  • 2.30-2.50 pm: Advanced on-board imaging for precision small animal proton and light ion radiation research
    Andrew Wroe | Miami Cancer Institute, Miami, USA
  • 3.10-3.25 pm: TBC
    Suresh Rana |Lynn Cancer Institute - Boca Raton Regional Hospital Boca Raton, Florida, USA

3.25-3.45 pm: Afternoon tea and industry exhibition

Session 4: New Era for BNCT

Session Chairs: Mitra Safavi-Naeni, James Vohradsky

  • 3.45-4.10 pm: BNCT: Past, present, and future
    Chad Lee, Vice President, Product at TAE LifeSciences
  • 4.10-4.25 pm: NCEPT- current status and future
    Mitra Safavi-Naeni | ANSTO, Australia
  • 4.25-4.40 pm: Current Status of research and development using the Linac-Based BNCT system at Tsukuba University
    Hiroaki Kumada | University of Tsukuba, Japan
  • 4.40-4.55 pm: Ultra-high-current lithium and carbon ion beams by direct plasma injection: a compact driver for accelerator-based BNCT
    Masahiro Okumura |Brookhaven National Laboratory, USA
  • 4.55-5.05 pm: Advancing Clinical BNCT: Technological developments in accelerator-based BNCT system
    Naonori Hu | Kansai BNCT Medical Center, Japan
  • 5.05-5.15 pm: Application of SOI microdosimetry in BNCT
    James Vohradsky | CMRP, University of Wollongong, Australia

6.00-8.00 pm: Welcome reception at Mantra Mooloolaba Beach - Harbour Room

Day 2: Tuesday 9 February 2027

8.00-8.20 am: Assemble committee and speakers for Session 1

Session 1: Microdosimetry state-of-the-art: present and future development and clinical use

Session Chairs: Anna Bianchi, Vladimir Pan

  • 8.20-8.40 am: Present and future of solid state microdosimetry
    Anatoly Rozenfeld | CMRP, University of Wollongong, Australia
  • 8.40-9.00 am: Towards traceable microdosimetry: A metrological perspective
    Giuseppe Schettino | National Physical Laboratory
  • 9.00-9.15 am: Linking microdosimetry to radiobiology: High-throughput spatial RBE mapping and DNA repair kinetics
    Fada Guan | MD Andersen Cancer Centre, USA
  • 9.15-9.35 am: Emerging opportunities in microdosimetry: multi-institutional intercomparisons and advancing measurement techniques
    Shannon Hartzel | Mayo Clinic, USA
  • 9.35-9.50 am: Microdosimetry in BNCT
    Gustavo Sabta Cruz | Comisión Nacional de Energía, Argentina 
  • 9.50-10.05 am: SOI-microdosimeter-based characterisation of carbon-ion beam radiation quality and intra-facility consistency
    Yaping Qi | National Institute of Metrology, China

10.05-10.35 am: Morning tea and industry exhibition

Session 2: Microdosimetry state-of-the-art: present and future development and clinical use continued

Session Chairs: Giuseppe Schettino, Shannon Hartzel

  • 10.35-10.50 am: Innovations in mini-TEPCs
    Anna Bianchi | Laboratori Nazionali di Legnaro, Italy
  • 10.50-11.05 am: SiC microdosimeter: Preliminary studies
    Sandra Barna | MedAustron, Austria
  • 11.05-11.20 am: Towards 2D silicon microdosimetry
    Linh Tran | CMRP, University of Wollongong, Australia
  • 11.20-11.35 am: Nanodosimetry in proton therapy
    Jan Gajewsky | Cyclotron Centre Bronowice, Poland

Session 3: Accelerator technology for future radiation therapy

Session Chair: Suzie Sheehy

  • 11.35 am-12.05 pm: Building on experience: The next chapter of MedAustron
    Dale Prokopovich | MedAustron, Austria
  • 12.05-12.25 pm: Proton therapy technical developments at Massachusetts General Hospital
    Benjamin Clasie | Massachusetts General Hospital, USA

12.25-1.30 pm: Lunch and industry exhibition

  • 1.30-1.45 pm: Toward ultra-fast proton therapy: technology demonstration of the novel 'TURBO’ beamline in Melbourne
    Suzie Sheehy | The University of Melbourne, Australia
  • 1.45-2.05 pm: MRT: State-of-the-art technology at Australian Synchrotron
    Daniel Hausermann | ANSTO Australian Synchrotron, Melbourne, Australia
  • 2.05-2.20 pm: PEER: Bridging accelerator physics, radiation research, dosimetry and instrumentation with ANSTO's high-energy electron beam facility
    Eugene Tan | ANSTO, Australia

Session 4: Targeted alpha therapy

Session Chair: Anatoly Rozenfeld

  • 2.20-2.45 pm: Current Status of radioisotopes and radiopharmaceuticals at KIRAMS
    Kyo Chul Lee | Korea Institute of Radiological & Medical Sciences, Korea
  • 2.45-3.00 pm: Accelerator-based production of Actinium-225: Building an Australian capability for targeted alpha therapy
    Graeme Melville | CMRP and SCMI, University of Wollongong, Australia
  • 3.00-3.15 pm: Alpha Glue
    Lujin Abu Sabah | University of Bristol, UK

3.15-3.45 pm: Afternoon tea and industry exhibition

Special session: AI in radiation therapy and medical imaging

Session Chairs: Stephanie Corradini, Lois Holloway

  • 3.45-4.10 pm: AI Overview
    Igor Barani | Barrow Neurological Institute, USA
  • 4.10-4.25 pm: Beyond range verification: New physical biomarkers for particle therapy PET
    Taiga Yamaya | National Institutes for Quantum Science and Technology, Japan
  • 4.25-4.40 pm: Biological washout: From a limitation to an opportunity in particle therapy PET
    Chie Toramatsu | National Institutes for Quantum Science and Technology, Japan

Special session: AI in radiation therapy and medical imaging

Session Chair: Michael Lerch

  • 4.40-5.00 pm: Virtual monochromatic imaging with linac-mounted photon counting detectors for next-generation IGRT
    Saree Alnaghy and Sean Hood | CMRP, University of Wollongong and Prince of Wales Hospital, Australia
  • 5.00-5.15 pm: Large-scale automated body composition analysis: Lessons learned and future directions
    Nick Hardcastle | Peter MacCallum Cancer Centre, Australia

Special session: Eye brachytherapy innovations

Session Chairs: Joel Poder, Stéphanie Corde

  • 5.15-5.40 pm: Navigating the physics workflow in ocular brachytherapy: treatment planning, dosimetry, and QA
    Frank-André Siebert | University Hospital Schleswig-Holstein (UKSH), Germany
  • 5.40-5.50 pm: Fast and accurate dose verification for I-125 and Ru-103 eye plaques
    Ilia Filipev | CMRP, University of Wollongong, Australia

5.50-6.00 pm: MMND Closing Remarks
Anatoly Rozenfeld, Michael Lerch, and Tomas Kron

Day 3: Thursday 11 February 2027

7.45-8.00 am: Assemble committee and speakers for session 1

8.00-8.10 am: Opening remarks
Anatoly Rozenfeld, Josh Yamada, Michael Jackson, Verity Ahem and Joseph Bucci

8.10-8.15 am: Official Opening of ITRO
Anatoly Rozenfeld, Josh Yamada

Session 1: Adaptive radiation therapy

Session Chairs: Michael Zelefsky, Paul Keall

Part 1: Perspective on real-time adaptive therapy

  • 8.15-8.45 am: Standard workflow for real-time adaptive therapy using Ethos: Advantages, limitations and future
    Jeremy Booth | Royal North Shore Hospital, Australia
  • 8.45-9.15 am: Standard workflow for real-time adaptive therapy using Unity for MR linac guidance: Advantages, limitations and future
    Michael Jameson | GenesisCare, Australia

Part 2: Adaptive radiotherapy for the treatment of prostate cancer- Making the workflows more efficient

  • 9.15-9.45 am: Role of AI in an adaptive radiotherapy workflow- What are we doing and what can we do better?
    Stefanie Corradini | Erlangen University Hospital, Germany
  • 9.45-10.15 am: Changing the standard paradigms of treatment planning and delivery with real adaptive therapy on the unity
    Michael Zelefsky | NYU Langone Medical Centre, USA
  • 10.15-10.45 am: Real-time image and dose-guided prostate cancer radiotherapy on X-ray linacs
    Paul Keall | The University of Sydney, Australia

10.45-11.15 am: Morning tea and industry exhibition

Session 2: MRI guided advanced brachytherapy

Session Chairs: Gil Cohen, Joel Poder and Annette Haworth

  • 11.15-11.45 am: Brachytherapy as the ultimate precision radiotherapy: are we measuring what matters?
    Frank-André Siebert | University Hospital Schleswig-Holstein (UKSH), Germany
  • 11.45 am-12.05 pm: From image guidance to adaptive radiotherapy: reinventing the brachytherapy workflow
    Gil'ad Cohen | NYU Langone Medical Center, USA
  • 12.05-12.25 pm: Does brachytherapy still matter in the era of prostate SBRT? Precision dose escalation, focal therapy and salvage
    Michael Zelefsky | NYU Langone Medical Centre, USA
  • 12.25-12.45 pm: Beyond the pelvis: interstitial brachytherapy as a local ablative therapy for liver tumours
    Stefanie Corradini | Erlangen University Hospital, Germany

Q&A and discussion: Annette Haworth and Associate Professor Joseph Bucci

12.45-1.45 pm: Lunch and industry exhibition

Session 3: Sarcoma

Session Chair: Michael Jackson

  • 1.45-2.30 pm: Changing paradigms in chordoma: Five decades of particle therapy from skull base to sacrum
    Shannon MacDonald | Southwest Florida Proton Centre, USA
  • 2.30-2.45 pm: Sarcoma Tumour Board
    Shannon MacDonald | Southwest Florida Proton Centre, USA

Session 4: Gastrointestinal (GI)

Session Chair: TBC

  • 2.45-3.30 pm: Advances and challenges in liver cancer radiation therapy
    Laura Dawson | Princess Margaret Cancer Center, Canada
  • 3.30-3.45 pm: GI Tumour Board
    Laura Dawson | Princess Margaret Cancer Center, Canada

3.45-4.15 pm: Afternoon tea and industry exhibition

Keynote 1: Changing paradigms in radiation oncology

4.15-4.45 pm: Repeat RT – motivation for novel paradigms in radiation oncology
Laura Dawson | Princess Margaret Cancer Center, Canada

Keynote 2: Changing paradigms in radiation oncology

4.15-4.45 pm: Indications for Upright Radiotherapy
Thomas “Rock” Mackie | LEO Cancer Care, USA

Day 4: Friday 12 February 2027

8.45-9.00 am: Assemble committee and speakers for Session 1

Session 1: Head and neck

Session Chair: Igor Barani

  • 9.00-9.45 am: Innovative approaches to deliver precision radiation for head and neck cancer
    Nancy Lee | Memorial Sloan Kettering Cancer Center, USA
  • 9.45-10.00 am: Head and Neck Tumour Board
    Nancy Lee | Memorial Sloan Kettering Cancer Center, USA
  • 10.00-10.30 am: Changing paradigms in chordoma: Long-term results of stereotactic radiosurgery as definitive treatment of chordomas of the spine
    Josh Yamada | Memorial Sloan Kettering Cancer Center, USA

10.30-11.00 am: Morning tea and industry exhibition

  • 11.00-11.30 am: SRS for brain tumours
    Igor Barani | Barrow Neurological Institute, USA
  • 11.30-11.45 am: Spine/Central Nervous System Tumour Board
    Josh Yamada | Memorial Sloan Kettering Cancer Center, USA

Session 2: Physics

Session Chair: TBC

  • 11.45 am-12.15 pm: Physiological and psychological evidence related to upright radiotherapy
    Thomas “Rock” Mackie | LEO Cancer Care, USA
  • 12.15-12.45 pm: Treatment planning recommendations for temporally modulated pulsed reduced rate radiation therapy (NRG-CC017)
    Wolfgang Tomé | Montefiore Medical Centre, USA

12.45-1.45 pm: Lunch and industry exhibition

Session 3: Spatially fractionated radiation therapy (SFRT)

Session Chair: Claire Phillips

  • 1.45-2.15 pm: TBC
    Valentin Djonov | University of Bern, Switzerland
  • 2.15-2.45 pm: Clinical Minibeam experience at Mayo Clinic
    Sean Park | Mayo Clinic, USA

2.45-3.45 pm: Afternoon tea and industry exhibition

Keynote 1: Changing paradigms in radiation oncology

3.45-4.15 pm: Future of Radiation Oncology:  Where are we and where we need to go
Nancy Lee | Memorial Sloan Kettering Cancer Center, USA

Keynote 2: Changing paradigms in radiation oncology

4.15-4.45 pm: Radiation therapy:  Moving beyond tumours
Josh Yamada | Memorial Sloan Kettering Cancer Center, USA

Day 5: Saturday 13 February 2027

7.45-8.00 am: Assemble committee and speakers for Session 1

Session 1:  Innovations in particle therapy

Session Chairs: Verity Ahern and Carl Rossi

  • 8.00-8.35 am: Advanced proton therapy
    Carl Rossi | California Protons Therapies Cancer, USA
  • 8.35-9.10 am: Treating children with protons: Lessons learned and emerging advances
    Shannon MacDonald | Southwest Florida Proton Centre, USA
  • 9.10-9.45 am: Carbon-ion and multi-ion therapy: QST experience and future perspectives
    Hitoshi Ishikawa | National Institutes for Quantum Science and Technology (QST), Japan
  • 9.45-10.15 am: Q&A and Discussion: proton and heavy ion therapy vs contemporary X-ray
    Carl Rossi, Verity Ahern, and Michael Jackson

10.15-10.45 am: Morning tea and industry exhibition

Session 2: Physics of particle therapy

Session Chairs: Tomas Kron and Thomas “Rock” Mackie

  • 10.45-11.15 am: Australian proton therapy program
    Verity Ahern | Western Sydney Local Health District, Australia
  • 11.15-11.30 am: RBE QA in proton and carbon ion therapy
    Anatoly Rozenfeld | CMRP, University of Wollongong, Australia
  • 11.30 am-12.00 pm: Predictive adaptive radiotherapy: Turning dose information into clinical decisions
    Stefan Both | University Medical Center Groningen, Netherlands
  • 12.00-12.15 pm: Cardio-respiratory gating for proton-based cardiac ablation
    Nicolas Depauw | Massachusetts General Hospital, USA
  • 12.15-12.30 pm: Why Not Both? Sequential IMRT/IMPT to extend the benefit of limited proton capacity
    Christian Velten | Medical University of South Carolina, USA
  • 12.30-12.45 pm: Q&A discussion
    Verity Ahern and Anatoly Rozenfeld

12.45-1.00 pm: ITRO closing remarks
Anatoly Rozenfeld, Josh Yamada, Michael Jackson, and Joseph Bucci

1.00-2.00 pm: Lunch and industry exhibition